Staff reporter at Night and Rest, covering Sleep.
A recent study published in the Journal of Clinical Sleep Medicine has found a significant increase in adverse event reports for oral appliances used to treat obstructive sleep apnea. The reports, which are filed with the FDA's MAUDE database, show a 10.1-fold increase in reports between 2024 and 2025 compared to the preceding four years.
The US Department of Health and Human Services (HHS) has introduced the Restorative & health-Enhancing Sleep Time (REST) program, aiming to develop closed-loop technologies that can objectively measure and correct poor sleep at home.
Sleep Review's CPAP adherence solutions guide compares options for managing CPAP adherence, a crucial aspect of treating obstructive sleep apnea.
CND Life Sciences has secured growth financing to expand its neurodiagnostics platform, which includes a skin biopsy-based test for diagnosing REM sleep behavior disorder and other synucleinopathies.
Eli Lilly and Company reports Q2 2026 financial results and updates on its clinical pipeline progress and business developments relevant to the sleep medicine industry.
The Centers for Medicare & Medicaid Services (CMS) has proposed a new family of Current Procedural Terminology (CPT) codes for unattended sleep testing, which will be based on the complexity of channels acquired and parameters reviewed, rather than the device used.
The Institute for Clinical and Economic Review (ICER) has published a final evidence report on oveporexton, a novel orexin receptor 2 agonist for narcolepsy type 1 (NT1). The drug received a B+ rating compared to no treatment and a C++ rating against active comparators. ICER suggests a benchmark price of $50,400 to $59,400 per year for the therapy, which has since gained FDA approval.
A recent study has shown that the Vida oral appliance, developed by Vivos Therapeutics Inc, can significantly reduce insomnia severity in patients. The study found that all 37 participants experienced symptom improvement, with an average reduction in Insomnia Severity Index scores of 65%.
The Board of Registered Polysomnographic Technologists (BRPT) has launched a completely redesigned website to improve the user experience for candidates, credential holders, and educators.
The owner of an Oregon-based sleep diagnostic testing company has pleaded guilty to conspiracy to commit healthcare fraud after overcharging federal agencies and private insurers for sleep studies.
The Restless Legs Syndrome (RLS) Foundation has published an updated treatment algorithm, providing practical guidance for clinicians in managing RLS. The algorithm replaces the 2021 version and is designed to complement the American Academy of Sleep Medicine's clinical practice guideline on RLS treatment.
The US Drug Enforcement Administration (DEA) has proposed transferring three dual orexin receptor antagonists (DORAs) from Schedule IV to Schedule V of the Controlled Substances Act.